This article requires a subscription to view the full text. If you have a subscription you may use the login form below to view the article. Access to this article can also be purchased.
- Michelle S Wright-Kanuth, PhD CLS(NCA)⇑
- Linda A Smith, PhD CLS(NCA)
- Address for correspondence: Michelle S Wright-Kanuth PhD CLS(NCA), Department of Clinical Laboratory Sciences, 301 University Boulevard, Galveston, TX 77555-1140. (409) 772-3055, definitions, clauses (409) 772-9470 (fax). mskanuth{at}utmb.edu
At the end of the article the learner will be able to:
Identify the major diseases treated with each of the components discussed.
Discuss the preparation of DLI and why CD4 cells are retained, while CD8 cells are depleted.
Describe the general process of making a dendritic cell vaccine.
Describe the different types of red cell substitutes and differentiate between them.
Explain at least two of the possible ways in which intravenous immunoglobulins may interact with the immune system.
Explain why cryoprecipitate reduced plasma is effective in treating thrombotic thrombocytopenia.
List and describe the platelet products under development.
Extract
Over the years, the significant role of blood components in treating certain diseases or conditions has been recognized. The use of these components has expanded as patients undergo chemotherapy for bone marrow ablation and require short-term component support. On the other hand, these transfusions can cause reactions ranging from mild to severe. Despite advances in serological testing for infectious disease agents, the risk of infectious complications from transfusion still remains. In addition, newly identified agents that may be transmitted via transfusion are constantly identified.
The cellular components most people are familiar with include packed red blood cells (PRBC), washed PRBC, leukoreduced PRBC, and pooled or apheresis platelets. Plasma products such as fresh frozen plasma (FFP) or crytoprecipitated anti-hemophiliac factor (CRYO), on the other hand, may not be as familiar. As our understanding of how the immune system functions and as technology has progressed, specialized components or manufactured products such as blood substitutes have been advanced as remedies to some of the complications with component transfusion or to meet the ever-increasing need for these products.
In this article we will focus on some of the new uses of common components and uncommonly used or newly developing components. We will discuss their origins, composition, and the conditions or diseases they are used to treat. These components include:
donor leukocyte infusions
dendritic cell vaccines
blood substitutes
novel platelet products and substitutes
intravenous immunoglobulin (IVIG)
fresh frozen plasma and cryosupernatant in therapeutic plasma exchange.
The variety of products and conditions…
ABBREVIATIONS:
AML = acute myeloid leukemia; APT = antigen presenting cell; CML = chronic myeloid leukemia; CRP = cryoprecipitate reduced plasma; CRYO = crytoprecipitated anti-hemophiliac factor; DC = dendritic cell; DCLHb = diaspirin cross-linked hemoglobin; DCLHb = diaspirin cross-linked hemoglobin; DLI = donor lymphocyte infusion; DMSO = dimethylsulfoxide; FFP = fresh frozen plasma; GVHD = graft-versus-host disease; GVL = graft-versus-leukemia; HbOC = hemoglobin-based oxygen carrier; HLA = human leukocyte antigens; IPMs = infusible platelet membranes; IVIG = intravenous immunoglobulin; LEHb = liposomes containing hemoglobin; PAP = prostatic acid phosphatase; PBMC = peripheral blood mononuclear cells; PEG = polyethylene glycol; POE = polyoxyethylene; PRBC = packed red blood cells; TPE = therapeutic plasma exchange.
- INDEX TERMS
- blood and platelet substitutes
- blood component therapy
- blood components
- novel blood components
At the end of the article the learner will be able to:
Identify the major diseases treated with each of the components discussed.
Discuss the preparation of DLI and why CD4 cells are retained, while CD8 cells are depleted.
Describe the general process of making a dendritic cell vaccine.
Describe the different types of red cell substitutes and differentiate between them.
Explain at least two of the possible ways in which intravenous immunoglobulins may interact with the immune system.
Explain why cryoprecipitate reduced plasma is effective in treating thrombotic thrombocytopenia.
List and describe the platelet products under development.
- © Copyright 2002 American Society for Clinical Laboratory Science Inc. All rights reserved.